EISAI CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1941-12-06

Employees: 11K

Market Cap: $12B

Website: http://www.eisai.co.jp

Clinical Trials

A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures

Not yet recruiting

Conditions: Partial-Onset Seizures
Primary Generalized Tonic-clonic Seizures

First Posted Date: 2024-10-24

Last Posted Date: 2024-10-24

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT06657378

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Recruiting

Conditions: Alzheimer's Disease

Interventions: Other: No Intervention

First Posted Date: 2024-03-21

Last Posted Date: 2024-06-17

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 5000

Registration Number: NCT06322667

Locations: 🇯🇵
Eisai trial site 1, Tokyo, Japan
🇯🇵
Eisai trial site 2, Hiroshima, Japan
🇯🇵
Eisai trial site 3, Kyoto, Japan

A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders

Completed

Conditions: Psychotic Disorders

Interventions: Other: No Intervention

First Posted Date: 2022-12-01

Last Posted Date: 2023-11-18

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 579728

Registration Number: NCT05633108

Locations: 🇬🇧
Eisai Ltd. European Knowledge Centre, Hatfield, Hertfordshire, United Kingdom

A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder

Phase 2

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Other: PBO
Drug: Lemborexant

First Posted Date: 2022-10-26

Last Posted Date: 2024-11-19

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 65

Registration Number: NCT05594589

Locations: 🇰🇷
Keimyung University Dongsan Hospital, Daegu-si, Korea, Republic of
🇰🇷
Gacheon University Gil Medical Centre, Incheon, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 6 locations

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants

Phase 1

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: E6742
Other: Placebo

First Posted Date: 2022-03-14

Last Posted Date: 2023-09-29

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05278663

Locations: 🇯🇵
Daido Clinic, Nagoya, Aichi, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵
Hospital of the University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

and more 9 locations

A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Dotinurad

First Posted Date: 2022-03-14

Last Posted Date: 2023-09-14

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05278676

Locations: 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, China

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Recruiting

Conditions: Lymphoma, Follicular

Interventions: Drug: Tazemetostat

First Posted Date: 2022-02-08

Last Posted Date: 2023-12-18

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 145

Registration Number: NCT05228158

Locations: 🇯🇵
Eisai Trial Site 149, Shinagawa-Ku, Tokyo, Japan
🇯🇵
Eisai Trial Site 77, Bunkyo-ku, Tokyo, Japan
🇯🇵
Eisai Trial Site 120, Komae-shi, Tokyo, Japan

and more 183 locations

A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Febuxostat
Drug: Dotinurad
Other: Febuxostat Matched Placebo
Other: Dotinurad Matched Placebo

First Posted Date: 2021-08-16

Last Posted Date: 2023-08-02

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 451

Registration Number: NCT05007392

Locations: 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Yanbian University Hospital, Yanji, Jilin, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China

and more 27 locations

A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)

Completed

Conditions: Parkinson Disease

Interventions: Drug: Equfina

First Posted Date: 2021-01-26

Last Posted Date: 2022-12-16

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 1088

Registration Number: NCT04724109

Locations: 🇯🇵
Eisai Trial Site 2, Osaka, Japan
🇯🇵
Eisai Trial Site 1, Tokyo, Japan

A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: E6742
Drug: Placebo

First Posted Date: 2020-12-24

Last Posted Date: 2021-07-20

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04683185

Locations: 🇯🇵
Eisai Trial Site #1, Bunkyō-Ku, Tokyo, Japan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy